Press Сentre
Наши новости
The expert believes that the first signs of degradation have appeared in the industry. To ensure real technological sovereignty it is necessary to replace 9% of INN of own innovative drugs. Such targets were announced at the meeting of the Expert Council in the State Duma, dedicated to the problems o pharma innovations development in 2025-2036.
...
14.02.2025
“HIV Infection: Transformation of Approaches and Effective Balance” IV All-Russian Congress with International Participation was held on December 19-20 in Moscow at the Analytical Center under the Government of the Russian Federation.
Andrey Ivashchenko, the Chairman of the Board of Directors of ChemRar Group took part in the business program ...
28.12.2024
On October 7, 2024, at the Gelendzhik Arena, “Development of Innovative Drugs As Condition for Technological Sovereignty of the Russian Federation in Pharmaceuticals” panel discussion was held within the framework of the Biotechmed-2024 Forum. The panel discussion was prepared with the support of ChemRar Group of Companies and the Innovative ...
25.10.2024
ChemRar Group, the domestic market leader in the development and manufacture of innovative pharmaceuticals, is expanding its manufacturing capacity by building a new high-tech complex that will include the manufacture of active pharmaceutical ingredients, storage facilities and a workshop for the development of intermediates for APIs.
...
19.09.2024
If we consider pharmaceuticals to be an industry where we should have technological sovereignty, then we should have not only fully localized pharmaceutical manufacturing facilities, but also our own development lines for innovative drugs.
On June 5, 2024, Andrey Ivashchenko, Chairman of the Board of Directors of ChemRar Group, Doctor of ...
14.06.2024
On June 5, within the framework of SPIEF, a session dedicated to the development of domestic innovative pharmaceuticals was held with the organizational support of Innopraktika Company and the National Champions Association.
As part of the discussion, the speakers considered the specifics of development, introduction into manufacture and launch ...
07.06.2024
Artificial Intelligence (AI) is now actively used in various industries, transforming and improving the processes efficiency. Medicine and pharmaceuticals are no exception, they are industries where AI technologies are being introduced into routine practice.
Development of new drugs is a long and expensive process; it is assumed that AI, by ...
27.04.2024
ChemRar Group and Pharmaceutical Health Corporation S.A.S, national pharmaceutical distributor in Colombia, announce the signing of the agreement for the supply of five anticancer products: TEMOSOLOMIDE (INN Temozolomide), LANGOTER (INN Gefitinib), SUNITINIB-CHEMRAR (INN Sunitinib), POTARBIN (INN Pazopanib) and LAPATINIB-CHEMRAR (INN Lapatinib). ...
15.04.2024
Andrey Aleksandrovich Ivashchenko, the Chairman of the Board of Directors of ChemRar Group, spoke at “Road to Sovereignty in Pharma and Healthcare” discussion organized by Kommersant Publishing House.
In June 2023, the Russian Government approved the Pharma-2030 Pharmaceutical Industry Development Strategy prepared by the Russian Ministry of ...
08.04.2024
April 2, a cycle of export-themed meetings has commenced at the office of the Russian Venture Company arranged by the National Champions Association in 2024.
The Export Champions Program is to support the international business activities of the rapid-growing hi-tech companies. The first topic on the agenda was the export of the pharmaceuticals ...
05.04.2024
Elpida informs that the auctions for centralized procurement of innovative medicines for HIV treatment have been successfully completed. In particular, the auctions for supply of 5,116,140 capsules (or 170,538 packs) of ELPIDA® COMBI and 13,382,820 capsules (or 446,094 packs) of ELPIDA® were held on January 17 and February 19, respectively.
...
07.03.2024
Over the past year, patient organizations have repeatedly reported that Russian HIV patients do not have enough dolutegravir . The original drug under the Tivicay brand is supplied to Russia by the British GSK. Initially, the active substance was protected by a patent until 2026, but then its validity was extended until 2029.
As Kommersant ...
30.01.2024
Публикации в печатных и электронных СМИ
Видео
Фото
